

Electronic Acknowledgement Receipt

EFS ID:	10260019
Application Number:	10587052
International Application Number:	
Confirmation Number:	7009
Title of Invention:	GEFITINIB SENSITIVITY-RELATED GENE EXPRESSION AND PRODUCTS AND METHODS RELATED THERETO
First Named Inventor/Applicant Name:	Paul A. Bunn Jr.
Customer Number:	22442
Filer:	Robert D. Traver/Robert Roe-Pachirat
Filer Authorized By:	Robert D. Traver
Attorney Docket Number:	5941-65-PUS
Receipt Date:	08-JUN-2011
Filing Date:	09-APR-2007
Time Stamp:	15:01:10
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	1393
Deposit Account	191970
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:
Charge any Additional Fees required under 37 C.F.R. Section 1.17 (Patent application and reexamination processing fees)

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		IDS_07.pdf	375821	yes	4
			723018076ff5480f1a00b447bb39ca16a42ef3c6		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Transmittal Letter		1	3	
	Information Disclosure Statement (IDS) Form (SB08)		4	4	
Warnings:					
Information:					
2	Foreign Reference	WO2004030625.pdf	1631169	no	39
			3f0de5b9b70f6121c8960776498eeacdf02bb97		
Warnings:					
Information:					
3	Non Patent Literature	Christensen_High_Levels_of_HER-2_Expression_Alter_the_Ability.pdf	2252393	no	10
			b99a2817a047d7b7d45e7b3b730a7cb45a00e2e3		
Warnings:					
Information:					
4	Non Patent Literature	HIRASHIMA_Protein_Overexpression_and_Gene_Amplification_of_c-erb_B-2_in_Pulmonary_Carcinomas.pdf	3408787	no	7
			7eb93595f2d16aeeb15bb97bd265b1192ab8c74f		
Warnings:					
Information:					
5	Non Patent Literature	NAKAMURA_Correlation_Between_Encoded_Protein_Overexpression_and_Copy_Number.pdf	1090058	no	6
			b0c0066560f243b7c3a4a0079b27c8e0d384deb2		
Warnings:					
Information:					
6	Non Patent Literature	TESTA_Chromosome_Abnormalities_in_Human_Non-Small_Cell_Lung_Cancer.pdf	1461637	no	6
			898d713d38f03ab3baecf9a174cd70273c0b6ebf		
Warnings:					
Information:					
7	Fee Worksheet (SB06)	fee-info.pdf	30788	no	2
			53b41aa86a520974ad863d1696d745c626b096e6		
Warnings:					
Information:					

This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.

New Applications Under 35 U.S.C. 111

If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.

National Stage of an International Application under 35 U.S.C. 371

If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.

New International Application Filed with the USPTO as a Receiving Office

If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.